{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:13:00Z","timestamp":1793747580270,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,19]],"date-time":"2014-04-19T00:00:00Z","timestamp":1397865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Gene Signal International SA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ophtha.2014.03.038","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T08:02:14Z","timestamp":1399363334000},"page":"1683-1692","source":"Crossref","is-referenced-by-count":102,"title":["Aganirsen Antisense Oligonucleotide Eye Drops Inhibit Keratitis-Induced Corneal Neovascularization and Reduce Need for Transplantation"],"prefix":"10.1016","volume":"121","clinical-trial-number":[{"clinical-trial-number":"2008-005388-33","registry":"10.18810\/euctr"}],"author":[{"given":"Claus","family":"Cursiefen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Viaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Geudelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavla","family":"Kadlecov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Al Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Thorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Majo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Frueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8510-9624","authenticated-orcid":false,"given":"Tobias","family":"Meyer-Ter-Vehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Geerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"B\u00f6hringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reinhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Meller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9701-8204","authenticated-orcid":false,"given":"Berthold","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2014.03.038_bib1","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/eye.2008.382","article-title":"Ocular immune privilege","volume":"23","author":"Taylor","year":"2009","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2014.03.038_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.preteyeres.2013.01.001","article-title":"Novel anti(lymph)angiogenic strategies for corneal and ocular surface disease","volume":"34","author":"Bock","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2014.03.038_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/IR:25:1:01","article-title":"Experimental corneal allograft rejection","volume":"25","author":"Gebhardt","year":"2002","journal-title":"Immunol Res"},{"key":"10.1016\/j.ophtha.2014.03.038_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.0818-9641.2002.01145.x","article-title":"The potential of antibody-based immunosuppressive agents for corneal transplantation","volume":"81","author":"Thiel","year":"2003","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.ophtha.2014.03.038_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00003226-200304000-00021","article-title":"Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology","volume":"22","author":"Cursiefen","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2014.03.038_bib6","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00003226-200007000-00025","article-title":"Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization","volume":"19","author":"Cursiefen","year":"2000","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2014.03.038_bib7","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.ophtha.2010.01.039","article-title":"Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis","volume":"117","author":"Bachmann","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.03.038_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/bjo.2011.204701","article-title":"Consensus statement on indications for anti-angiogenic therapy in the management of corneal disease associated with neovascularisation: outcome of an expert roundtable","volume":"96","author":"Cursiefen","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.03.038_bib9","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1167\/iovs.05-0105","article-title":"Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis","volume":"46","author":"Andrieu-Soler","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2014.03.038_bib10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1124\/jpet.108.147496","article-title":"Potent in\u00a0vivo antiangiogenic effects of GS-101 (5\u2032-TATCCGGAGGGCTCGCCATGCTGCT-3\u2032), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1","volume":"329","author":"Al-Mahmood","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.ophtha.2014.03.038_bib11","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1167\/iovs.11-9064","article-title":"Anti-angiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration","volume":"53","author":"Cloutier","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2014.03.038_bib12","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation: Miltefosine for the treatment of Acanthamoeba keratitis. EMA\/COMP\/139086\/2005 Rev. 4. Updated December 10, 2013. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2009\/10\/WC500006373.pdf. Accessed March 13,\u00a02014."},{"key":"10.1016\/j.ophtha.2014.03.038_bib13","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.ophtha.2009.04.016","article-title":"GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial","volume":"116","author":"Cursiefen","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.03.038_bib14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.exer.2008.08.007","article-title":"Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts","volume":"87","author":"Bock","year":"2008","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2014.03.038_bib15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0161-6420(13)38009-9","article-title":"Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics: ETDRS report number 7","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.03.038_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","article-title":"New visual acuity charts for clinical research","volume":"94","author":"Ferris","year":"1982","journal-title":"Am J Opthalmol"},{"key":"10.1016\/j.ophtha.2014.03.038_bib17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/eye.2008.86","article-title":"The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration","volume":"22","author":"Dadgostar","year":"2008","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2014.03.038_bib18","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0161-6420(94)31138-9","article-title":"Risk factors for corneal graft failure and rejection in the Collaborative Corneal Transplantation Studies","volume":"101","author":"Maguire","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.03.038_bib19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0161-6420(92)31960-8","article-title":"Factors predictive of corneal graft survival. Report from the Australian Corneal Graft Registry","volume":"99","author":"Williams","year":"1992","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.03.038_bib20","series-title":"National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25), version 2000 (interviewer administered format)","year":"1996"},{"key":"10.1016\/j.ophtha.2014.03.038_bib21","first-page":"1017","article-title":"The National Eye Institute Visual Function Questionnaire: experience of the ONTT","volume":"41","author":"Cole","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2014.03.038_bib22","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumad versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2014.03.038_bib23","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2014.03.038_bib24","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2014.03.038_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1755-3768.2011.02312.x","article-title":"The association between corneal neovascularization and visual acuity: a systematic review","volume":"91","author":"Bachmann","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.03.038_bib26","unstructured":"European Medicines Agency. European Regulatory Workshop\u2013Ophthalmology-Summary and Report: Clinical Development, Scientific Advice and Paediatric Investigation Plans. EMA\/450332\/2012. August 31, 2012. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2012\/09\/WC500131815.pdf. Accessed March 13,\u00a02014."},{"key":"10.1016\/j.ophtha.2014.03.038_bib27","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1172\/JCI20465","article-title":"VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment","volume":"113","author":"Cursiefen","year":"2004","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ophtha.2014.03.038_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2012.07.002","article-title":"Pathogenesis of herpes stromal keratitis\u2013a focus on corneal neovascularization","volume":"33","author":"Gim\u00e9nez","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2014.03.038_bib29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4049\/jimmunol.175.1.509","article-title":"Application of plasmid DNA encoding IL-18 diminishes development of herpetic stromal keratitis by antiangiogenic effects","volume":"175","author":"Kim","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ophtha.2014.03.038_bib30","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/S0002-9440(10)63267-1","article-title":"Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis","volume":"165","author":"Kim","year":"2004","journal-title":"Am J Pathol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014003157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014003157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T05:54:53Z","timestamp":1538632493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642014003157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0161642014003157"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2014.03.038","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}